Platinum Priority – Kidney CancerEditorial by Axel Bex and Noel Clarke on pp. 919–920 of this issueThe Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus
Introduction
Venous tumor thrombi are reported to be present in approximately 10% of patients with renal cell carcinoma (RCC) [1], [2]. Up to 60% of these patients also have concurrent subclinical metastases [3]. The current treatment paradigm in this population is radical nephrectomy and tumor thrombectomy. Aggressive resection is necessary because at this time it is the only known curative therapy for locally advanced RCC [2]. However, the risk of perioperative morbidity and mortality from radical nephrectomy and thrombectomy increases in conjunction with the level of the thrombus [1]. Neoadjuvant systemic therapy may potentially decrease the tumor thrombus burden and thus improve the safety and feasibility of resection. Additionally, neoadjuvant therapy is appealing because it may allow early treatment of occult micrometastatic disease, potentially improving the curative potential of surgical resection.
In the current literature only a few case reports have described the effect of neoadjuvant targeted molecular therapy (TMT) on tumor thrombus level [4], [5], [6], [7], [8], [9], [10]. These limited studies indicate promising results in terms of reducing the size and level of the thrombus; however, the appropriate use of neoadjuvant therapy in this setting remains to be determined. The aim of our investigation was to study the clinical effect of systemic TMT on the in situ RCC tumor thrombus size and level.
Section snippets
Patient population
We retrospectively reviewed a prospectively maintained bi-institutional database from the University of Texas Southwestern Medical Center and MD Anderson Cancer Center, consisting of 208 patients treated with TMT for in situ RCC. We specifically evaluated patients in this database with RCC in situ primary tumors and venous tumor thrombi. All patients had biopsy confirmation of RCC histology before institution of TMT. The tumor thrombus level was defined as I, renal vein only; II, inferior vena
Patient characteristics
A total of 25 patients were treated with TMT with an in situ caval RCC tumor thrombus (Table 1). There were 14 male and 11 female patients. The median age was 58.5 yr (range: 41.5–74.2 yr) and median Eastern Cooperative Oncology Group performance status was 1 (range: 0–3). Percutaneous biopsy of the renal mass before instituting therapy showed histology of clear cell RCC (ccRCC) in 19 and unclassified RCC in 6. The tumor thrombus level was II in 18 patients (72%), III in 5 (20%), and IV in 2
Discussion
The only potential cure in patients with locally advanced RCC, including those with a venous tumor thrombus, is complete surgical resection. The effort to resect the tumor thrombus completely can be challenging and is associated with an overall complication rate between 10% and 40% [1], [15]. The thrombus level has also been shown to correlate with surgical morbidity and mortality. Karnes and Blute reported their experience with 659 patients with venous tumor thrombi and showed an increase in
Conclusions
Review of a large series of patients treated with systemic targeted therapy with in situ RCC tumor thrombi revealed minimal clinical effect on the tumor thrombus level and failed to demonstrate a significant impact on the surgical approach in those proceeding to thrombectomy. Interestingly, only patients treated with primary sunitinib had measurable thrombus regression; however, the magnitude and clinical relevance of this effect is not clear. The overall cytoreductive effect of targeted
References (25)
- et al.
Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus
Urology
(2007) - et al.
Prognostic factors for renal cell carcinoma with tumor thrombus extension
J Urol
(2007) - et al.
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi
Eur Urol
(2008) - et al.
Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma
Eur Urol
(2009) - et al.
Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes
J Urol
(2005) - et al.
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma
J Urol
(2009) - et al.
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy
Urology
(2008) - et al.
Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma
J Urol
(2010) - et al.
Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma
Eur Urol
(2011) - et al.
Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus
Nat Clin Pract Urol
(2008)